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IP, formation and histamine rcleasc from rat peritoneal mast cells stimulated by compound 48/80 were dose-dependently inhibited by BtsAMP. 
These inhibitions were restored to the control level in lhe presence of H-8, u protein kinase A inhibitor. The 22 kDaprotein in masl cells was revealed 
as a markedly phosphorylated protein by incubating with B&AMP, and this phosphorylation was also diminished by H-8. The 22 kDa 
phosphoprotcin of rat mast cells comigrated with phosphorylatcd smg p2 IB, purified from human platelets and phosphorylated by protein kinase 
A in cell-free system, in both one- and two-dimensional PAGE analysis. Moreover, 22 kDa protein in mast cells was identified as smg ~218 by 
immunoblot analysis using an antibody against smg p2lB. From 111~ present study, it became clear that smg p21B is phosphorylated by means 
of protein kinase A system in rat peritoneal mast cells, and it was assumed that phosphorylatcd smg p2lB plays some important role in the 
suppression of IP, formation and histamine release from rat peritoneal mast cells. 
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1. INTRODUCTION proteins having molecular weights of 240,50,24 and 22 
kDa [5,6]. 
It is known that protein phosphorylation plays some 
Ciitid rOks iii the iXgr;!~~iO~ Cf various cel!ular re- 
sponses and functions. So far, many protein kinases 
have been identified, and protein kinase A and C in 
particular have been shown to be involved in a wide 
variety of cell functions [I ,2]. We first demonstrated the 
existence of vimentin, an intermediate filament protein, 
in rat peritoneal mast cells, and that this protein was 
phosphorylated after stimulation with some histamine 
releasers. Further, we found that this phosphorylation 
proceeded in the presence of protein kinase C [3]. By 
contrast, the substrate protein(s) of protein kinase A 
and its physiological functions in rat mast cells remains 
to be identified. In platelets, prostacyclin has been 
shown to increase the CAMP level through stimulation 
of adenylate cyclase, which is effective in leading the 
inhibition of platelet functions [4]. Moreover, the acti- 
vation of protein kinase A elicited by increased intracel- 
lular CAMP increases the phosphorylation of several 
In rat peritoneal mast cells, it is known that an in- 
crease in CAMP level is effective in inhibiting histamine 
release [1,7,8]. One possible mechanism of CAMP in 
inhibitory reaction is assumed to be prevention of Ca2” 
release from intracellular Ca store [9]. Although the 
inhibitory effect of CAMP on histamine release fram rat 
mast cells is exerted in association with the activation 
of protein kinase A, the exact mechanism of the interac- 
tion between CAMP and protein kinase A is not known. 
To clarify this point, the present investigation was car- 
ried out. 
2. MATERIALS AND METHODS 
2.1 I Muterids and chemicals 
Corrcsporrrhrce address: ‘x. Tnsaka, Department of Pharmacology, 
Faculty of PharnraceuGcal Sciences, Okayama University, Okayama 
700. Japan. Fax: (81) (862) 55-7456. 
The catalytic subunit of protein !&xi% A was purified from bovine 
heart according to the method of &vo et al. [IO]. smg p21B was 
purified to near homogeneity from human platciet membranes ii lj. 
Compound 48180 and BYAMP were obtained from Sigma Chemical 
Co. (St Louis, MO, USA). ATP and H-S were purchased from 
Yamasa Shoyu Co. (Chiba, Japan) and Seikagaku Kogyo CO. flokyo. 
Japan), respectively. [3zP]Orthophosphoric acid (specific activity 370 
TBq/ mmol) and [r.32PJATP (specific activity 222 TBqimmol) wele 
purchased from DuPont/New England Nuclear and Am&lam Corp., 
respectively. Other materials and chemicals were obtained from corn- 
merciul sources. 
Abbreviations: protein kinasc A, cyclic AMP-dependent prolein ki- 
nase; protein kinasc C, Caz’/phorpholipid-dcpcndenl protein kinas<; 
G proGn, GTP-binding protein; Bt2cAMP, @,Ol’-dibutyryl cyclic 
AMP; SDS, sodium dodecyl sulfate; PAGE, polyacrylamidc gel elec- 
_- trophoissis; PMSF, phs L, .*.a* .A,. ".."..,..."Y.."., w-l, YI. ,.ssc!- 1 ,~---..-.th.~~~~lr~~.,i rl.,nr:A(P. r.nE r.nn A: 
ciation stimulator; IP,, inositol 1,4,5-trisphosphatc; PIP1. phosphati- 
dylinositol 4,5-bisphosphnte; PGE,, prostaglandin E,. 
2.2. Nistanlino release from rat peritoncat mast cells 
Rat peritoneal mast cells were isolated from the abdominal cavity 
of male Wistar rats (3OO-r100 g) to more than 95% homogeneity as 
previously described [ 121. The mast ails were suspended inphysiolog- 
ical salt solution (PSS) consisting of 154 mM NaCI, 2.7 mM KCI, 0.9 
mM CaC12, 10 mM HEPES/NaOH (pH 7.4) and 5.6 mM &tcc% The 
ccl1 suspension (5 x 1oJ cells/100 ~1) was incubated for 5 min at 37% 
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and 100~1 of test drugs were added. After incubation with test drugs 
for I5 min at 37”C, 50~1 of compound 48/80 were added to make a 
final concentrntion of 0.5 pug/ml and the incubation proceeded for 10 
min at 37OC. Theamount of histamine in the supernalant and residual 
histamine in the cells were measured by automated Ruorometric assay 
1131. 
2.3. Measurement of IP, contrast irl rat peritoneal 111~91 cells 
Rnt mast cells (3 x lo6 cells4100 yl) were treated with test drugs for 
15 min at 37°C. and then the cells were stimulated with compound 
48/80 for 5 s as previously dcscribcd [14]. The reaction was terminated 
by the addition of 50~1 of 30% trichloroacetic acid. The mixture was 
placed on ice for 30 min and centrifuged at 15,000 rpm for 10 min at 
4’C to remove the acid-insoluble materials. The supernatant (250 ~1) 
was neutralized with an equal volume of ice-cold Freon-amine [12]. lPJ 
cotrients in the aqueous upper phase were measured by means of IP, 
assay kit (Amcrsham). 
2.4. Proreh phosphorytarion in rat peritoneal mast cells 
Purified rat mast cells were labeled with 3zP (0.5 mCi/ml) in phos- 
phate-free Dulbecco’s modified Eagle’s medium (Nissui, Japan) for 30 
min nt 37OC, and washed twice with PSS as previously described [3]. 
31P-labeled mt mast cells (LO6 ce11~100 ~1) were incubated for 5 min 
at 37OC, and then, 100 yl of test drugs were added and incubated for 
another 15 min. The reaction was terminated by the addition of an 
equal volume of SDS-sample buffer containing 1 SO mM Tris-I-K1 (PI-i 
6.8), 4% SDS, 4% 2-mercaptoethanol, 20% glycerol and 0.02% Bromo- 
phenol blue, and the mixture was heated for 3 min in a boiling water 
bath. The sample was subjected to SDS-PAGE using lo-20% poly 
acrylamide gradient slab gel (Uaiichi Pure Chemicals Co., Japan) [15]. 
After clectrophorcuis, the gel was stained with Coomassie brilliant 
blue, destained, dried and exposed to nn X-ray film (Hyperfilm-MR, 
Amersham). The autoradiogrnms were scanned with a laser densitom- 
eter (Molecular Dynamics) to quantify the relative radioactivity. 
For two-dimensional PAGE, the reaction wns stopped by the addi- 
tion of an equal volume of an isoelectric focusing lysis buffer contain- 
ing 9 M urea, 2% (w/v) Nonidet P-40,2% (v/v) ampholytes (pH range 
3.5-10) and 5% 2-mercaptocthanol. This sample was subjected to 
two-dimensional PAGE by the method ofO’Farrel1 [16] using 2% (v/v) 
ampholytes (pi-l range 35-10) in the first dimension and IO-20% 
polyacrylamide gradient gel in the second dimension. 
2.5, Prorein phosphorylation of smg p21B in cell-free system 
Phosphorylation of smg ~2113 (220 ng of protein) was carrid out 
by the catalytic subunit of protein kinase A (50 ng of protein) in a 
reaction mixture (50~1) containing SO mM Tris/HCl (pH 7.5), 10 mM 
MgClz, 4 mM dithiothreital, 100pg/ml bovine serum albumin, 0.15% 
sodium cliolatc and 25 PM [$‘P]ATP (0.1 &i/SO ~1) for 10 min at 
30°C. The reaction was terminated by the addition of an equal volume 
of SDS-sample buffer or isn?!~!ric focusing lysis buffer as described 
above. The samples wcrc subjcctcd to one-dimensional or two-dimen- 
sional PAGE, followed by autoradiopraphy. 
2.6. Immunologirat LtecGon of stng p2IB 
Rat peritoneal mast cells (lo7 cells) were suspended in 50~1 of 1% 
Nonidet P-40. 20 mM Tris-HCI IRH 7.41. 5 mM EDTA and 1 mM 
PMSF, and incubated for 30 min‘it 4’C’The detergent-soluble mast 
cell proteins and purified smg p21B (IS ng of protein) were subjected 
to SDS-PAGE, and were electrophorcticdlly transferred from gel to 
a polyvinylidcnc dilluoridc membrane (lmmobilon. Millipore), The 
msmbranc was incubated for 2 h at 37’C in blocking solution (phos- 
phate-buffered saline (PBS) containing 3% bovine serum albumin and 
3% skim milk (Difco)). Then, the membrane was incubated with anti- 
smg p21 B antiserum diluted 1:lSO in blocking solution for 2 h at 37OC. 
After themembrane was washed three times with PBScontainingO.l% 
Tween 20, the incubation was continued with biotinylated &oiit anti- 
rabbit IgG (Vector). The immuno-reactive protein was detected with 
nn avidin-biotinylatcd horseradish pcroxidase complex (Vcctastain 
ARC kit, Vector). 
3. RESULTS 
Rat peritoneal mast cells were incubated with 
Bt,cAMP and then stimulated by 0.5 pg/ml of com- 
pound 48/80. In control cells, compound 48/80 (0.5 ,ug/ 
ml) released about 50% of the total histamine, and the 
amount of IP3 formed within 5 s increased to approxi- 
mately 9 times that of the resting cells. As shown in Fig. 
lA, Bt,cAMP induced a dose-dependent inhibition of 
histamine release from rat peritoneal mast cells. At a 
concentration of 1 mM, Bt,cAMP inhibited histamine 
release by approximately 70% In order to examine 
whether or not this inhibitory effect of CAMP is exerted 
in association with the activation of protein kinase A, 
the effect of H-8, a protein kinase A inhibitor [17], was 
investigated. When various concentrations of H-8 were 
added with 1 mM of &CAMP during the preincubation 
period, &CAMP-induced histamine release inhibition 
was dose-dependently restored by H-8, and the maxi- 
mum effect of H-8 was reached at 100 ,uM (Fig. 1B). 
When mast cells were-exposed to compound 48/80 for 
5 s, the intracellular content of IP3 increased to approx- 
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Fig. 1. Effects of B&AMP and H-8, a protein kinase A inhibitor, on 
histamine release and TP, formation in rat peritoneal mast cells. Hisla- 
mine release was cliched by compound 48180 (0.5 &ml) for 10 min. 
(A) The inhibitory effect of Bt$AMP on histamine release from rat 
mast cells. (6) The restoring effect of H-8 on BYAMP-induced hista- 
mine release inhibition. (C) The inhibitory effect of B&AMP on IP, 
formation in rat mast cells. (D) The restoring cffezt of H-8 on Bt, 
CAMP-induced inhibition of 1P3 formation. The results indicate the 
means ?z SEM (n = 4). 
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Fig. 2. Protein phosphorylation induced by B&AMP in rat mast cells. (A) Protein phosphorylation i rat mast cells. (Lane 1) Untreated control; 
(lane 2) rat mast cells were treated with 1 mM of BtsAMP; (lane 3) mt mast cells were treated with 1 mM of &CAMP plus 100,uM of M-S. (B) 
Dose-dcpendcnt phospholylation of 22 kDa protein in rat mast cells induced by ERIcAMP. The results indicate the means -t-SEM (n = 4). 
imatcly 9 times that of the control. The amount of IP3 
formed by compound 48/80 was also inhibited by pre- 
treatment with Bt,cAMP at the same concentration 
range (Fig. 1C). Moreover, Bt$AMP-induced inhibi- 
tion of IP3 formation was dose-dependently restored by 
the presancc of H-8 as iii the case of histarkx rckase 
(Fig. 1D). These results seem to suggest hat the inhib- 
itory effects of CAMP in mast cells might be related to 
both the amount of activated protein kinase A and the 
amount of target protein phosphorylated by protein 
kinase A. 
Next, protein phosphorylation in rat peritoneal mast 
cells exposed to &CAMP was investigated. As shown 
in Fig. 2A, when rat mast cells were incubated with 1 
mM of Bt,cAMP, several proteins were 
phosphoryiated. Pn particular, 22 kDa protein was 
markedly phosphorylated, as shown in Fig. 2A {lane 2). 
However, phosphorylation of 22 kDa protein was 
clearly inhibited in the presence of 100 PM of H-8 (Fig. 
2A, lanes 3). F&CAMP-induced phosphorylation of 22 
kDa protein increased in a dose-dependent manner 
(Fig. 2B) and reached a maximum at 1 mM of 
Bt+AMP. The concentration of Bt,cAMP necessary for 
protein phosphorylation was the same as the concentra- 
tion of F&CAMP required in inhibiting histamine re- 
lease and IP3 formation, as shown in Fig. 1. The same 
molecular weight (22 kDa) of phosphorylated protein 
has been reported in platelet [5,61, and this was identified 
as smg ~21, a ras-related small molecular weight G 
protein [6]. But, it is not known whether or not smg 
p21B exists in rat peritoneal mast cells. As shown in Fig. 
3.4, smg p21B was detected as a single protein band 
(lane 1) when rat mast cell proteins were tested in the 
immunoblot analysis using anti-smg p21 B antiserum. 
This protein band had the same molecular weight as 
that of purified human platelet smg p21B (Fig. 3A, lane 
2). The 22 kDa protein phosphorylated in response to 
Bt,cAMP in rat mast cells had the same molecular 
weight as the smg p21B phosphorylated by protein ki- 
nase A in cell-free system (Fig. 3B, lane 1 and 2). When 
these two were r-i-A un,-~ subjected to SDS-PAGE, two . . . ..__ -.1- 
proteins comigrated to the same position (Fig. 3B, lane 
3). To confirm whether or not these two proteins are 
identical, the 22 kDa phosphorylated protein in rat mast 
cells and phosphorylated smg p21B were subjected to 
two-dimensional PAGE [16]. One radioactive spot was 
observed as phosphorylated smg ~216 (Fig. 4A). 
Fig. 4C shows the autoradiogram of the protein phos- 
phorylation in rat peritoneal mast cells induced by 1 
mM of B&AMP. The phosphorylated 22 kDa protein 
(4 (W 
0 22kDa 
1 2 123 
Fig. 3. Immunoblot analysis of smg p2 IB and BtsAMP-indud PFO- 
tein phosphorylation of rat mast cells. (A) Lane 1, rat mast cell pro- 
teins; lane 2, purified human platelet smg p2IB. (B) Lane 1, 
phuspho@‘& smg ~2% bi pzotck kiase .A< !ax 2, phosphorylated 
proteins in rat mast cells elicited by 1 mM of BtsAMP; lane 3, 
phosphorylated proteins in mt mast cells plus phosphorylated smg 
p21B. 
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Fig. 4. Two-dimensional PAGE analysis of protein phospharyladcn 
by Bt$AMP in rat mast cells. (A) smg p21B phosphorylated by pro- 
tein kinasr A. (B) Protein phosphorylation in rat mast cells in 
the absence of Bt,cAMP. (C) Protein phosphorylation i rat mast cells 
induced by I mM of &CAMP. (D) Phosphorylated protein in rat mast 
cells cliched by Bt,cAMP plus phosphorylatcd smg p21 B by protein 
kinsse A. Arrows indicate phosphorytatcd smg ~2113 (A), the 22 kDa 
phosphorylated protein in rat mast cells (C) and the mixture (D: 
A plus C). 
appeared as one spot and its position was the same as 
that of phosphorylated smg p2lB. When phosphor- 
ylated 22 kDa protein in mast cells and phosphorylated 
smg ~21 B were mixed and subjected to two-dimensional 
PAGE, these two proteins comigrated together showing 
exactly the same molecular weight and the same isoelec- 
tric point (Fig. 4D). These results clearly indicate that 
smg ~21 B is located in rat peritoneal mast ce!!s, and that 
22 kDa protein, which is phosphorylnted by protein 
kinase A in rat mast cells in the presence of increased 
CAMP level, is ‘smg p2lB’. 
4. DISCUSSION 
It is known that when rat mast cells are treated so as 
to increase intracellular CAMP contents, histamine re- 
lease is significantly inhibited [1,7,8]. We also reported 
that intracellular Ca*+ concentrations and histamine re- 
lease incluced by histamine releasers were inhibited by 
pretre~tm~nb rrith Bt,cAMP 1183. Moreover, an increase C_._.____ . _... 
in IP3 formation elicited by compound 48/80 was also 
inhibited by pretreatment with F&CAMP (Fig. 1C). As 
shown in Fig. 1B and D, it is clear that the inhibitory 
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effects of CAMP on histamine release and on IPJ forma- 
tion take place in association with protein kinase A 
activation, since H-S was effective in reversing these 
inhibitory reactions. So far, in rat peritoneal mast cells 
the direct substrate protein(s) for protein kinase A re- 
main to be identified. We found that 22 kDa protein was 
markedly phosphorylated by treatment with Bt,cAMP 
(Fig. 2A and B). However, this phosphorylated protein 
was not detected in either compound 48/80- or sub- 
stance P-stimulated rat peritoneal mast cells [3]. In 
human platelets, four proteins of 240,50,24 and 22 kDa 
have been shown to be phosphorylated in response to 
PGE,, a CAMP-elevating agent, and 22 kDa 
phosphorylated protein was estimated as smg p21 B [6]. 
As shown in one- andfmo-dimensional PAGE (Figs. 3B 
and 4), 22 kDa protein phosphorylated in response to 
Bt2cAMP in rat peritoneal mast cells comigrates with 
purified smg p21B; this seems to indicate that these two 
proteins have the same molecular weights and isoelec- 
tric points. Moreover, smg p2lB exists in rat peritoneal 
mast cells as indicated by the immunoblot analysis using 
anti-smg p2lJ3 antiserum (Fig. 3A). Protein kinase A 
phosphorylates smg p21B mainly at Ser”“, which is 
located between the polybasic region and the geranyl- 
geranylated cysteine residue in the C-terminal region 
[19]. This C-terminal region is essential to interact with 
the stimulatory GDP/GTP exchange protein named 
smg GDS l2OJ. When smg ~21 B was phosphoryiatecl by 
protein kinase A, it markedly increased the action of 
smg GDS and initiated the conversion from GDP- 
bound inactive form to the GTP-bound active form [19]. 
It is known that smg p21B has the same putative effec- 
tor domain and consensus C-terminal sequences as the 
ras gene products [11,20]. Therefore, it is possible to 
assume that smg p21B exerts actions similar to, or an- 
tagonistic to, those of the ras gene products [6,21]. 
Wakelam et al. showed that normal ~21~““” might be 
involved in the regulation of receptor-linked phospho- 
lipase C activation without affecting the increase of re- 
ceptor numbers [22], Lapetina and Reep also reported 
that ras-like 29 kDa G protein might regulate phospho- 
lipase C activity in htiman piatelets [23]. Moreover, the 
activation of PIP,-specific phospholipase C was 
prompted by the addition of small molecular weight G 
protein [24,X]. It has been reported that IP, formation 
in human platelets was inhibited by pretreatment with 
prostacyclin, a potent adenylate cyclase activator [4], 
lPs formation, induced by compound 48180 in rat mast 
cells, was also inhibited by the pretreatment with 
Bt,cAMP (Fig. lC), and this inhibitory action was re- 
stored by H-S in a dose-dependent fashion (Fig. 1D). 
lPB promotes Ca” release from intracellular Ca? store 
and released Ca2+ is essential for triggering .histamine 
rekase from rat peritoneal mast cells [9;12,18!. The in- 
hibitory effects (to histamine release and IP, formation) 
of Bt,cAMP and 22 kDa protein phosphorylation were 
induced at the same concentration range of Bt,cAMP. 
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It is possible that smg p21B is phosphorylated by pro- 
tein kinase A in response to increased intracellular 
cANP levels, and that at least some parts of the inhib- 
itory actions of protein kinase A system in rat mast cells 
are exerted by smg p21B. Although it is not known 
whether phospholipase C in mast cells is also regulated 
by small molecular weight G protein, it can be assumed 
that phosphorylated smg p21B is useful to convert 
GDP-bound inactive form to GTP-bound active form, 
and consequently, it may inhibit phospholipase C acti- 
vation by the antagonistic action to phospholipase C- 
activated G protein. 
In this experiment, we first demonstrated that smg 
p2lB exists in rat peritoneal mast cells and that it is 
phosphorylated by activation of protein kinase A. Fur- 
ther, it was assumed that smg p2lB may play some 
important role in inhibitiug histamine release from rat 
peritoneal mast cells. 
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